Metsigletic

Active Ingredient:: Metformin Hydrochloride, Sitagliptin
Origin:: EU

Metsigletic (Metformin Hydrochloride, Sitagliptin)

Q: What is Metsigletic used for?

Metsigletic is prescribed for adult patients with type 2 diabetes mellitus who need additional glycaemic control beyond diet, exercise, or metformin alone. The combination of metformin and sitagliptin targets both hepatic glucose production and incretin‑mediated insulin secretion, helping to lower blood glucose levels.

Q: How does Metformin Hydrochloride work?

Metformin Hydrochloride reduces hepatic glucose output and improves peripheral insulin sensitivity, which lowers fasting and post‑prandial blood glucose. Sitagliptin, the second component, blocks the DPP‑4 enzyme, increasing incretin hormones that stimulate insulin release only when glucose is elevated, providing complementary glucose‑lowering effects.

Q: What is the usual dose of Metsigletic?

The dose of Metsigletic is individualized by the prescribing healthcare professional based on the patient’s renal function, glycaemic targets, and prior therapy. The prescriber determines the appropriate strength and dosing schedule, which may be adjusted during treatment to achieve optimal blood‑sugar control.

Q: Is Metsigletic safe in pregnancy or breastfeeding?

Safety data for Metsigletic in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

Q: How do I order Metsigletic from GNH India?

To request Metsigletic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Q: How does Metsigletic compare with other antidiabetic options?

Metsigletic combines metformin, a first‑line biguanide, with sitagliptin, a DPP‑4 inhibitor, offering dual mechanisms in a single tablet. Compared with separate tablets, it reduces pill burden. Relative to other fixed‑dose combos such as Janumet, the efficacy and safety profiles are similar, but individual patient factors and cost considerations guide selection.

Q: What are the storage and handling requirements for Metsigletic?

Metsigletic tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Q: How is Metsigletic administered?

Metsigletic is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a full glass of water. Consistency in timing helps maintain stable drug levels, but patients should follow any specific instructions regarding meals or other medications.

Q: What are the most serious risks associated with Metsigletic?

The most serious risks include lactic acidosis, a rare but potentially fatal condition linked to metformin, especially in patients with renal impairment or hypoxia. Severe hypoglycaemia can occur when combined with insulin or sulfonylureas. Acute pancreatitis and serious allergic reactions are also rare but important to monitor.

Q: Who should not use Metsigletic?

Metsigletic is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin, sitagliptin, or any excipients, and those with metabolic acidosis, including diabetic ketoacidosis. Caution is also advised for individuals with significant hepatic disease or a history of pancreatitis.

Metformin Hydrochloride, the active ingredient in Metsigletic, is a Biguanide presented as a tablet for oral use. It is combined with Sitagliptin, a DPP‑4 inhibitor, to treat type 2 diabetes mellitus in adult patients requiring improved glycaemic control. It is indicated for patients who have not achieved target HbA1c with monotherapy.

GNH India supplies Metsigletic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides full regulatory documentation to support importers and healthcare providers.

Manufacturer / TM Owner

Zaklady Farmaceutyczne Polpharma S.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Metsigletic, a combination of metformin and sitagliptin, is used in the management of type 2 diabetes mellitus.

Type 2 diabetes mellitus: improves glycaemic control when added to diet, exercise and other antidiabetic agents.
Inadequate response to metformin alone: provides additional HbA1c reduction for patients not reaching targets on metformin monotherapy.
Combination therapy simplification: merges two complementary mechanisms into a single oral tablet, reducing pill burden.

How It Works

Metformin decreases hepatic gluconeogenesis and enhances peripheral insulin sensitivity, thereby lowering fasting glucose levels. Sitagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which results in increased endogenous incretin hormones (GLP‑1 and GIP). The elevated incretins promote glucose‑dependent insulin secretion and suppress glucagon release, together achieving better overall glycaemic control.

Side Effects

Metsigletic may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects

Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
Metallic taste in the mouth.
Headache.
Decreased appetite.

Serious or Rare Side Effects

Lactic acidosis: a rare but life‑threatening condition, especially in patients with renal impairment.
Severe hypoglycaemia: particularly when combined with sulfonylureas or insulin.
Acute pancreatitis: sudden onset abdominal pain with elevated enzymes.
Allergic reactions: rash, angioedema, or anaphylaxis.
Hepatic dysfunction: abnormal liver enzymes or hepatitis.

Precautions & Warnings

Before initiating Metsigletic, clinicians should consider several safety aspects.

Renal function: assess eGFR and monitor periodically; avoid in severe renal impairment.
Hepatic function: contraindicated in patients with significant liver disease.
Lactic acidosis risk: avoid in conditions predisposing to hypoxia or metabolic acidosis.
Pregnancy and lactation: use only if potential benefit justifies the potential risk to the fetus or infant.
Drug interactions: review concomitant medications for agents that may affect metformin or sitagliptin levels.
Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Metsigletic can interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid)

Severe renal impairment (eGFR <30 mL/min/1.73 m²): increased risk of metformin accumulation and lactic acidosis.
Potent CYP2C8 inhibitors (e.g., gemfibrozil): may raise metformin plasma concentrations.
Concurrent sulfonylureas or insulin: heightened risk of severe hypoglycaemia.

Moderate Interactions (Monitor Closely)

Alcohol consumption: can potentiate metformin‑related lactic acidosis.
Iodinated contrast agents: temporary discontinuation of metformin is recommended before and after imaging.
Diuretics (e.g., thiazides): may affect renal clearance of metformin, requiring dose adjustment.
Beta‑blockers: may mask hypoglycaemia symptoms.
ACE inhibitors or ARBs: monitor renal function and electrolytes.

Frequently Asked Questions

Metsigletic is prescribed for adult patients with type 2 diabetes mellitus who need additional glycaemic control beyond diet, exercise, or metformin alone. The combination of metformin and sitagliptin targets both hepatic glucose production and incretin‑mediated insulin secretion, helping to lower blood glucose levels.

Metformin Hydrochloride reduces hepatic glucose output and improves peripheral insulin sensitivity, which lowers fasting and post‑prandial blood glucose. Sitagliptin, the second component, blocks the DPP‑4 enzyme, increasing incretin hormones that stimulate insulin release only when glucose is elevated, providing complementary glucose‑lowering effects.

The dose of Metsigletic is individualized by the prescribing healthcare professional based on the patient’s renal function, glycaemic targets, and prior therapy. The prescriber determines the appropriate strength and dosing schedule, which may be adjusted during treatment to achieve optimal blood‑sugar control.

Safety data for Metsigletic in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Metsigletic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metsigletic combines metformin, a first‑line biguanide, with sitagliptin, a DPP‑4 inhibitor, offering dual mechanisms in a single tablet. Compared with separate tablets, it reduces pill burden. Relative to other fixed‑dose combos such as Janumet, the efficacy and safety profiles are similar, but individual patient factors and cost considerations guide selection.

Metsigletic tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Metsigletic is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a full glass of water. Consistency in timing helps maintain stable drug levels, but patients should follow any specific instructions regarding meals or other medications.

The most serious risks include lactic acidosis, a rare but potentially fatal condition linked to metformin, especially in patients with renal impairment or hypoxia. Severe hypoglycaemia can occur when combined with insulin or sulfonylureas. Acute pancreatitis and serious allergic reactions are also rare but important to monitor.

Metsigletic is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin, sitagliptin, or any excipients, and those with metabolic acidosis, including diabetic ketoacidosis. Caution is also advised for individuals with significant hepatic disease or a history of pancreatitis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 08 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.